放射性碘难治性分化型甲状腺癌再分化治疗研究进展

国际肿瘤学杂志››2024,Vol. 51››Issue (7): 464-467.doi:10.3760/cma.j.cn371439-20231008-00076

放射性碘难治性分化型甲状腺癌再分化治疗研究进展

刘晶¹, 张俊²()

¹大连医科大学研究生院，大连 116044
²南京医科大学附属泰州人民医院核医学科，泰州 225300

收稿日期:2023-10-08修回日期:2024-02-16出版日期:2024-07-08发布日期:2024-08-14
通讯作者:张俊，Email：dr.junzhang@njmu.edu.cn

Progress in the study of redifferentiation therapy for radioactive iodine-refractory differentiated thyroid carcinoma

Liu Jing¹, Zhang Jun²()

¹Graduate School， Dalian Medical University， Dalian 116044， China
²Department of Nuclear Medicine， Affiliated Jiangsu Taizhou People's Hospital of Nanjing Medical University， Taizhou 225300， China

Received:2023-10-08Revised:2024-02-16Online:2024-07-08Published:2024-08-14
Contact:Zhang Jun， Email：dr.junzhang@njmu.edu.cn

摘要/Abstract

摘要：

分化型甲状腺癌总体预后良好，但仍有少部分患者会出现局部复发和远处转移，在初始或治疗过程中丧失摄碘能力，成为放射性碘难治性分化型甲状腺癌（RAIR-DTC），预后较差。RAIR-DTC患者治疗方法有限，且效果欠佳，通过药物促进再分化使RAIR-DTC恢复摄碘能力是治疗的重要策略之一。

关键词:碘放射性同位素,甲状腺肿瘤,细胞去分化,分子靶向治疗

Abstract:

The overall prognosis of differentiated thyroid cancer is good， but a small number of patients will still develop local recurrence and distant metastasis， and lose iodine uptaking ability in the initial or treatment process， becoming radioactive iodine-refractory differentiated thyroid carcinoma （RAIR-DTC）， with a poor prognosis. Treatment options for RAIR-DTC patients are limited with poor results， and restoration of iodine uptaking capacity in RAIR-DTC through pharmacological promotion of redifferentiation is one of the important strategies for treatment.

Key words:Iodine radioisotopes,Thyroid neoplasms,Cell dedifferentiation,Molecular targeted therapy

刘晶, 张俊. 放射性碘难治性分化型甲状腺癌再分化治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(7): 464-467.

Liu Jing, Zhang Jun. Progress in the study of redifferentiation therapy for radioactive iodine-refractory differentiated thyroid carcinoma[J]. Journal of International Oncology, 2024, 51(7): 464-467.

参考文献24

[1]	Haymart MR. Progress and challenges in thyroid cancer management[J].Endocr Pract,2021,27(12): 1260-1263. DOI:10.1016/j.eprac.2021.09.006.
[2]	Filetti S, Durante C, Hartl D, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J].Ann Oncol,2019,30(12): 1856-1883. DOI:10.1093/annonc/mdz400. pmid:31987292
[3]	Liu JR, Liu YQ, Lin YS, et al. Radioactive iodine-refractory differentiated thyroid cancer and redifferentiation therapy[J].Endocrinol Metab (Seoul),2019,34(3): 215-225. DOI:10.3803/EnM.2019.34.3.215.
[4]	Singh A, Ham J, Po JW, et al. The genomic landscape of thyroid cancer tumourigenesis and implications for immunotherapy[J].Cells,2021,10(5): 1082. DOI:10.3390/cells10051082.
[5]	Riesco-Eizaguirre G, Santisteban P, De la Vieja A. The complex regulation of NIS expression and activity in thyroid and extrathyroidal tissues[J].Endocr Relat Cancer,2021,28(10): T141-T165. DOI:10.1530/ERC-21-0217.
[6]	Cazarin J, Dupuy C, Pires de Carvalho D. Redox homeostasis in thyroid cancer: implications in Na⁺/I^-symporter (NIS) regulation[J].Int J Mol Sci,2022,23(11): 35682803. DOI:10.3390/ijms23116129.
[7]	Oh JM, Ahn BC. Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS[J].Theranostics,2021,11(13): 6251-6277. DOI:10.7150/thno.57689. pmid:33995657
[8]	Hu JW, Yuan IJ, Mirshahidi S, et al. Thyroid carcinoma: phenotypic features, underlying biology and potential relevance for targeting therapy[J].Int J Mol Sci,2021,22(4): 1950. DOI:10.3390/ijms22041950.
[9]	Cai X, Wang R, Tan J, et al. Mechanisms of regulating NIS transport to the cell membrane and redifferentiation therapy in thyroid cancer[J].Clin Transl Oncol,2021,23(12): 2403-2414. DOI:10.1007/s12094-021-02655-0. pmid:34100218
[10]	Dunn LA, Sherman EJ, Baxi SS, et al. Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers[J].J Clin Endocrinol Metab,2019,104(5): 1417-1428. DOI:10.1210/jc.2018-01478. pmid:30256977
[11]	Ho AL, Dedecjus M, Wirth LJ, et al. Selumetinib plus adjuvant radioactive iodine in patients with high-risk differentiated thyroid cancer: a phase Ⅲ, randomized, placebo-controlled trial (ASTRA)[J].J Clin Oncol,2022,40(17): 1870-1878. DOI:10.1200/JCO.21.00714.
[12]	Jaber T, Waguespack SG, Cabanillas ME, et al. Targeted therapy in advanced thyroid cancer to resensitize tumors to radioactive iodine[J].J Clin Endocrinol Metab,2018,103(10): 3698-3705. DOI:10.1210/jc.2018-00612. pmid:30032208
[13]	Iravani A, Solomon B, Pattison DA, et al. Mitogen-activated protein kinase pathway inhibition for redifferentiation of radioiodine refractory differentiated thyroid cancer: an evolving protocol[J].Thyroid,2019,29(11): 1634-1645. DOI:10.1089/thy.2019.0143. pmid:31637953
[14]	Leboulleux S, Do Cao C, Zerdoud S, et al. A phase Ⅱ redifferentiation trial with dabrafenib-trametinib and¹³¹I in metastatic radioactive iodine refractory BRAF p.V600E-mutated differentiated thyroid cancer[J].Clin Cancer Res,2023,29(13): 2401-2409. DOI:10.1158/1078-0432.CCR-23-0046.
[15]	Tchekmedyian V, Dunn L, Sherman E, et al. Enhancing radioiodine incorporation in BRAF-mutant, radioiodine-refractory thyroid cancers with vemurafenib and the anti-ErbB3 monoclonal antibody CDX-3379: results of a pilot clinical trial[J].Thyroid,2022,32(3): 273-282. DOI:10.1089/thy.2021.0565. pmid:35045748
[16]	National Cancer Institute (NCI).Dabrafenib and lapatinib in treating patients with refractory thyroid cancer that cannot be removed by surgery[EB/OL]. (2023-09-20) [2023-12-21]. https://classic.clinicaltrials.gov/ct2/show/NCT01947023.
[17]	Nikitski AV, Condello V, Divakaran SS, et al. Inhibition of ALK-signaling overcomes STRN-ALK-induced downregulation of the sodium iodine symporter and restores radioiodine uptake in thyroid cells[J].Thyroid,2023,33(4): 464-473. DOI:10.1089/thy.2022.0533.
[18]	Song J, Qiu W, Deng X, et al. A somatic mutation of RasGRP3 decreases Na⁺/I^-symporter expression in metastases of radioactive iodine-refractory thyroid cancer by stimulating the Akt signaling pathway[J].Am J Cancer Res,2018,8(9): 1847-1855.
[19]	Hanna GJ, Busaidy NL, Chau NG, et al. Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase Ⅱ study[J].Clin Cancer Res,2018,24(7): 1546-1553. DOI:10.1158/1078-0432.CCR-17-2297.
[20]	Zhang K, Li C, Liu J, et al. DNA methylation alterations as therapeutic prospects in thyroid cancer[J].J Endocrinol Invest,2019,42(4): 363-370. DOI:10.1007/s40618-018-0922-0. pmid:29992502
[21]	Fu H, Cheng L, Sa R, et al. Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbou-ring BRAF^V600Eby synergistically decreasing global trimethylation of H3K27[J].J Cell Mol Med,2020,24(6): 3336-3345. DOI:10.1111/jcmm.15007.
[22]	Wächter S, Damanakis AI, Elxnat M, et al. Epigenetic modifications in thyroid cancer cells restore NIS and radio-iodine uptake and promote cell death[J].J Clin Med,2018,7(4): 61. DOI:10.3390/jcm7040061.
[23]	Groener JB, Gelen D, Mogler C, et al. BRAF^V600Eand retinoic acid in radioiodine-refractory papillary thyroid cancer[J].Horm Metab Res,2019,51(1): 69-75. DOI:10.1055/a-0765-9078.
[24]	Pak K, Shin S, Kim SJ, et al. Response of retinoic acid in patients with radioactive iodine-refractory thyroid cancer: a meta-analysis[J].Oncol Res Treat,2018,41(3): 100-104. DOI:10.1159/000484206. pmid:29485411